To see the other types of publications on this topic, follow the link: 621.361 6.
Journal articles on the topic '621.361 6'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic '621.361 6.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Sueyoshi, Shuzo, and Takeshi Morikawa. "Erratum to: Visual Influence of Wood Used in Workplace Interiors [Mokuzai Gakkaishi Vol.62 (2016) No.6 p.311-316]." Mokuzai Gakkaishi 63, no. 1 (2017): 56. http://dx.doi.org/10.2488/jwrs.63.56.
Full text
2
Booth, Christopher M., Michael J. Raphael, Xuejiao Wei, Claudio Soares, Philippe L. Bedard, Michael Leveridge, D. Robert Siemens, and Andrew George Robinson. "Utilization of mental health services among survivors of testicular cancer: A population-based study." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e16062-e16062. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e16062.
Full textAbstract:
e16062 Background: Testicular cancer survivors may experience long-term psychological distress related to their diagnosis and treatment. Measurement of mental health service use (MHS) is an objective way to quantify the incurred burden of psychological distress. Here we describe patterns of MHS use among survivors of testicular cancer in a single-payer health system. Methods: The Ontario Cancer Registry was linked to electronic treatment records to identify all incident cases of testicular cancer treated with orchiectomy in the Canadian province of Ontario during 2004-2010. Mental health clinical visits were identified from records of hospital admission, emergency room visits and out-patient physician billing records. Results: The study cohort included 1877 patients; mean age was 35 and 61% had pure seminoma. Two thirds of patients (66%, 1230/1877) were initially treated with active surveillance. In the 2-year period prior to orchiectomy, 24% (443/1877) of patients had MHS use. Post-orchiectomy, the prevalence of MHS use was 18% (331/1877), 23% (431/1877) and 30% (572/1877) at 6, 12 and 24 months, respectively. The use of MHS was greatest in the peri-diagnostic/surgical period. Rates of MHS visits, 3 months before, 0-3 months after, 4-6 months after and 2 years after orchiectomy were 11%, 14%, 10%, and 6%, respectively. Post-orchiectomy MHS use was greatest among those with baseline MHS use. The prevalence of MHS use for patients with and without baseline MHS use was 40% (175/443) vs 11% (156/1434, p < 0.001) at 6 months; 51% (225/443) vs 14% (206/1434, p < 0.001) at 12 months; and 61% (271/443) vs 21% (301/1434, p < 0.001) at 24 months post-orchiectomy. Post-orchiectomy MHS use did not vary by initial treatment strategy (active surveillance vs upfront treatment, p = 0.435). Older patients were more likely to have MHS visits at all time periods than younger patients; MHS rates at 6 months were 15% (93/631) vs 18% (112/625) vs 20% (126/621) for ages 16-29, 30-39, and 40+ years respectively (p = 0.035). Conclusions: MHS use among survivors of testicular cancer is common, particularly in the peri-diagnostic and surgical period. The rate of MHS use is highest among those patients with a history of prior MHS use. Clinicians should screen for the presence of psychological distress among survivors of testicular cancer.
3
Prausová, Romana, Zuzana Kozelková, and Lenka Šafářová. "Protocol for acclimatization of in vitro cultured Potamogeton praelongus – aspect of plantlet size and type of substrate." Acta Societatis Botanicorum Poloniae 84, no. 1 (2015): 35–41. http://dx.doi.org/10.5586/asbp.2015.003.
Full textAbstract:
<p>The aim of the experiment was to determine suitable substrate type and optimal plant size for transfer of plantlets from in vitro to ex vitro under experimental outdoor conditions. Tests focused on the effect of substrate type (muddy and sandy) and starting size of plantlets gained through in vitro seed germination (0–3, 3.1–5,5.1–6, 6.1–10 cm) on plant growth. Three parameters (fresh weight, length, and the number of leaves) were compared to evaluate growth. Basic water parameters in experimental water tanks were regularly measured (pH, temperature, electrical conductivity, shadow intensity) and controlled to reach similar conditions to those in the natural habitat of this species. Overwintering was studied in a cellar with newly defined size categories (≤6, 6.1–8, 8.1–10, 10.1–12, 12.1–15 cm).</p><p>Both substrate type and starting size of plantlets significantly impacted growth. Plantlets grew better in the muddy substrate while a 100% success rate of rooting was gained with a starting size of 6.1–10 cm in both substrates. The biggest increase in fresh weight was observed with a starting size of 3.1–5 cm and 5.1–6 cm in both substrates. The greatest increase in fresh weight was observed in plants with a starting size of 3.1–5 cm in the muddy substrate (more than 95% increase). The best overwintering results were gained in the 6.1–8 cm size category.</p>
4
Strati, Gina L., Julious L. Willett, and Frank A. Momany. "Ab initio computational study of β-cellobiose conformers using B3LYP/6-311++G**." Carbohydrate Research 337, no. 20 (November 2002): 1833–49. http://dx.doi.org/10.1016/s0008-6215(02)00267-7.
Full text
5
Smith, N. A. F. "Gunther Garbrecht. Hydraulics and Hydraulic Research. A Historical Review. Rotterdam and Boston: A.A. Balkema, 1987. Pp. ix + 362. ISBN 90-6191-621-6. £53.50." British Journal for the History of Science 22, no. 1 (March 1989): 116–17. http://dx.doi.org/10.1017/s0007087400025887.
Full text
6
HEERING, PETER. "OLIVER HOCHADEL, Öffentliche Wissenschaft:Elektrizität in der deutschen Aufklärung. Göttingen: Wallstein, 2003. 364 pp., ISBN 3-89244-629-6." Nuncius 20, no. 1 (January 1, 2005): 253–55. http://dx.doi.org/10.1163/221058705x00965.
Full text
7
Harrison, Melissa, Beverly Bell, Allen Chauvenet, Joanne Kurtzberg, Bruce Camitta, and Meenakshi Devidas. "Testicular Relapse in Lesser, Standard, and High Risk Patients Treated with Frontline Therapy for Childhood ALL. Pediatric Oncology Group Protocols 9201, 9405, 9605, and 9406." Blood 108, no. 11 (November 16, 2006): 1863. http://dx.doi.org/10.1182/blood.v108.11.1863.1863.
Full textAbstract:
Abstract From 1984–94, testicular relapse (TR) was reported in 10–20% of boys with ALL. Addition of intermediate and higher dose methotrexate (MTX) in subsequent trials may have reduced this risk. Pediatric Oncology Group (POG) trials 9201, 9405, 9605, and 9406 for B-precursor ALL opened in 1994–6. Protocol 9201 enrolled 365 lesser risk, 9405: 158 standard risk, 9605: 601 standard risk, and 9406: 512 higher risk (total 1,636) boys with ALL. All studies used a common induction protocol of L-asparaginase, vincristine, and prednisone. Doxorubicin was added for higher risk (based on age, initial WBC, and CNS/testicular status). Overt testicular disease at diagnosis was present in only 7/512 (1.4%) boys, all on 9406; they later received radiation therapy to the testicles. After induction, patients were assigned to POG protocols based on NCI risk criteria. Patients on 9201 received 6 courses of IV MTX (1g/m2) during intensification and once or twice daily oral 6-MP during continuation. Patients on 9405 were randomized to 1 or 2.5 g/m2 IV MTX for 12 courses during consolidation and once or twice daily oral 6-MP during continuation. Patients on 9605 received 6 courses of 1g/m2 IV MTX in consolidation and were randomized to +/− 6 months of divided dose oral MTX during intensification and once or twice daily oral 6-MP during continuation. Study 9406 randomized to 6 courses of 1 or 2.5g/m2 IV MTX and to standard or high dose AraC during intensification. TR was overt (physical exam) or occult (biopsy). 99 boys had isolated or combined TR. 0/7 with testicular disease at diagnosis had TR. Of the boys with TR, only 3 did not receive a significant amount of the total therapy. Lesser risk patients had the lowest incidence of TR and lowest overall mortality rate of 1/11(9.1%). Higher risk patients had more relapses during therapy, 11/32(34%) and highest overall mortality rate of 13/32(40.6%). Isolated TR was more common than combined, except on 9406. Median time to TR off therapy was 7.5 months (range 1–52). Median age at relapse was 9.4 years (range 1.8–22). Mortality post any type of second relapse after TR was 60% compared to 25% for those without second relapse(p=0.0124). Table 1 9201 9405 9605 9406 # Pts. 365 158 601 512 # TR 11(3.0%) 13(8.2%) 43(7.1%) 32(6.3%) Isolated TR, ON Rx/OFF Tx 8(2.2%),1/7 7(4.5%),1/6 30(5.0%),4/26 16(3.1%),6/10 Combined TR, ON Rx/OFF Rx 3(0.8%),0/3 6(3.9%),2/4 13(2.2%),2/11 16(3.1%),5/11 Median(Range)# of mos. off Rx 5(2–46) 11(1–28) 7(1–52) 8(1–42) Median(Range)Age at Relapse (yrs.) 6(4.4–15.6) 8.1(1.8–22) 8.3(3.4–21) 12.4(3–20.4) Table 2 Type of TR Count(%) Second Relapse(%) Overall Mortality(%) *Other includes 6-TR+CNS and 1-TR+Subcutaneous mass in cheek. Isolated TR 61/99 (61.6) 18/61 (13.1) 18/61 (29.5) TR+Marrow 31/99 (31.3) 5/31 (16.1) 10/31 (32.3) TR+Other 7/99 (7.1) 2/7(28.6) 2/7 (28.6) Overall TR rate on these studies was approximately 6%. Risk stratification, augmentation of therapy and use of intermediate and high dose MTX may have contributed to this reduction.
8
Jette, Diane U., Mary Stilphen, Vinoth K. Ranganathan, Sandra Passek, Frederick S. Frost, and Alan M. Jette. "Interrater Reliability of AM-PAC “6-Clicks” Basic Mobility and Daily Activity Short Forms." Physical Therapy 95, no. 5 (May 1, 2015): 758–66. http://dx.doi.org/10.2522/ptj.20140174.
Full textAbstract:
BackgroundThe interrater reliability of 2 new inpatient functional short-form measures, Activity Measure for Post-Acute Care (AM-PAC) “6-Clicks” basic mobility and daily activity scores, has yet to be established.ObjectiveThe purpose of this study was to examine the interrater reliability of AM-PAC “6-Clicks” measures.DesignA prospective observational study was conducted.MethodsFour pairs of physical therapists rated basic mobility and 4 pairs of occupational therapists rated daily activity of patients in 1 of 4 hospital services. One therapist in a pair was the primary therapist directing the assessment while the other therapist observed. Each therapist was unaware of the other's AM-PAC “6-Clicks” scores. Reliability was assessed with intraclass correlation coefficients (ICCs), Bland-Altman plots, and weighted kappa.ResultsThe ICCs for the overall reliability of basic mobility and daily activity were .849 (95% confidence interval [CI]=.784, .895) and .783 (95% CI=.696, .847), respectively. The ICCs for the reliability of each pair of raters ranged from .581 (95% CI=.260, .789) to .960 (95% CI=.897, .983) for basic mobility and .316 (95% CI=−.061, .611) to .907 (95% CI=.801, .958) for daily activity. The weighted kappa values for item agreement ranged from .492 (95% CI=.382, .601) to .712 (95% CI=.607, .816) for basic mobility and .251 (95% CI=.057, .445) to .751 (95% CI=.653, .848) for daily activity. Mean differences between raters' scores were near zero.LimitationsRaters were from one health system. Each pair of raters assessed different patients in different services.ConclusionsThe ICCs for AM-PAC “6-Clicks” total scores were very high. Levels of agreement varied across pairs of raters, from large to nearly perfect for physical therapists and from moderate to nearly perfect for occupational therapists. Levels of agreement for individual item scores ranged from small to very large.
9
Hokkanen, Ann-Helena, Laura Hänninen, Johannes Tiusanen, and Matti Pastell. "Vasikan uni hyvinvointitutkimuksissa." Suomen Maataloustieteellisen Seuran Tiedote, no. 26 (January 31, 2010): 1–4. http://dx.doi.org/10.33354/smst.75779.
Full textAbstract:
Riittävä uni on tärkeää vasikan hyvinvoinnille. Erityisen tärkeää uni ja lepo ovat nuorille kasvaville eläimille, joiden aivot kehittyvät vielä. Uni ja leporytmin muutokset ovat uusimpia hyvinvointia kuvaavia mittareita.Tuotantotiloilla saattaa olla pikkuvasikan uneen merkittävä vaikutus, sillä epämiellyttävät ympäristöolosuhteet voivat heikentää unen laatua. Useat erilaiset ympäristötekijät vaikuttavat yksilön uneen, samoin kipu. Kivuliaan yksilön uni sirpaloituu ja kipu heikentää unen laatua, kun taas unen puute vahvistaa kipukokemusta. Tuotantoeläinten unesta ja kivusta ei ole tehty tieteellisiä tutkimuksia. Tähän asti vasikan unta on tuotantoympäristöissä voitu mitata vain kannettavalla EEG-laitteistolla tai tarkkailemalla eläinten käytöstä. EEG-laitteisto on kallis ja häiritsee eläintä. Käyttäytymistarkkailu puolestaan vie paljon aikaa. Tavoitteenamme oli kehittää langaton mittalaite, aktigrafi, vasikan unen mittaamiseen.Kiinnitimme kevyen, langattoman kiihtyvyysanturin 10 vasikan kaulapantaan. Vasikat olivat alle 6 viikon ikäisiä ja ne pidettiin tutkimuksen ajan olkikuivitetussa ryhmäkarsinassa. Laite kiihtyvyyden kolmen akselin suhteen 25 Hz taajuudella ja 2 g:n mittausalueella. Videoimme vasikoiden käytöstä yhtäjaksoisesti 24 tunnin ajan ja rekisteröimme keskimääräisen päivittäisen keston kokonaisuniajalle sekä, vilkeunelle (REM) ja hidasaaltounelle (NREM) vasikan lepoasennoista käyttäen CowLog-ohjelmaa.Alustavat tulokset ovat valmiina kuudelta vasikalta. Aluksi unta ennustava malli (SVM luokittelija) kehitettiin kolmella vasikalla ja mallin toimivuus testattiin kolmella muulla vasikalla. Lopulliset tulokset saadaan 10 vasikalta. Aktigrafidatasta unta ennustivat parhaiten mallissa keskimääräinen kiihtyvyys, kiihtyvyyden vaihtelu ja wavelet-varianssi. Mallin antamien ennusteiden ja käyttäytymistarkkailun tulosten eroavaisuutta verrattiin t-testillä.Malli ennusti kokonaisuniajan 93 ∓ 3 % tarkkuudella sekä päivittäisen NREM- ja REM-unen määrän 89 ∓ 9 % ja 83 ∓ 2 % tarkkuudella. Kokonaisuniajassa sekä NREM- ja REM-unen kokonaiskestoissa ei ollut tilastollisesti merkitseviä eroja käyttäytymistarkkailun ja unta ennustavan mallin välillä (621 vs. 602 min, 351 vs. 339 min, 316 vs. 351 min).Kehitimme aktigrafin, jolla mitata vasikoiden unikäyttäytymistä langattomasti yhtä tarkasti kuin käyttäytymistä tarkkaillen. Laite mahdollistaa vasikoilla jatkuvan unimittauksen tuotantoolosuhteissa häiritsemättä eläintä.
10
Bardak, Handan, Yavuz Bardak, Yeşim Erçalık, Burak Erdem, Gökhan Arslan, and Semrin Timlioglu. "Sequential tissue plasminogen activator, pneumatic displacement, and anti-VEGF treatment for submacular hemorrhage." European Journal of Ophthalmology 28, no. 3 (May 2018): 306–10. http://dx.doi.org/10.5301/ejo.5001074.
Full textAbstract:
Purpose: To report the results of our sequential intravitreal (IV) tissue plasminogen activator (tPA), pneumatic displacement (PD), and IV anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD)-related submacular hemorrhage (SMH). Methods: A total of 16 eyes of 16 patients with SMH of less than 15 days duration were included in this retrospective pilot study. The tPA was applied on the day of diagnosis, and PD was performed the following day. Patients received 3 consecutive monthly IV injections of ranibizumab starting from 15 days after PD. During the follow-ups, additional ranibizumab treatment was performed if persistent macular or recurrent subretinal or intraretinal fluid hemorrhage was observed. Results: The mean central retinal thickness was 489 ± 92 μm (311-621 μm) at the time of diagnosis, 324 ± 56 μm (209-409 μm) at the first month, 262 ± 48 μm (197-364 μm) at 3 months, 248 ± 40 μm (190-334 μm) at 6 months, and 253 ± 41 μm (192-356 μm) at the last control (p<0.01). The mean best-corrected visual acuity was 2.08 ± 0.79 logMAR (0.7-3.0 logMAR) at baseline, 1.41 ± 0.70 logMAR (0.56-2.50 logMAR) at the first month, 1.21 ± 0.66 logMAR (0.3-2.0 logMAR) at 3 months, 1.14 ± 0.77 logMAR (0.2-2.50 logMAR) at 6 months, and 1.09 ± 0.73 logMAR (0.3-2.50 logMAR) at the last follow-up (p<0.01). Conclusions: Sequential IV tPA, PD, and IV anti-VEGF treatments for SMH in patients with nAMD is effective. However, further studies are needed to establish the best treatment algorithm for SMH in patients with nAMD.
11
Sorokin, Yu V., B. L. Demin, L. A. Smirnov, and Е. G. Kalimulina. "Perfection of a technology of processing and utilization of fine fractions of dump slag." Ferrous Metallurgy. Bulletin of Scientific , Technical and Economic Information 76, no. 6 (July 21, 2020): 620–24. http://dx.doi.org/10.32339/0135-5910-2020-6-620-624.
Full textAbstract:
Processing of old dumps slag at crushing-sorting facilities results in a large yield of slag fine fractions – screening. Because of high content of metal inclusions and powder-like fraction in the screening, this product often becomes unclaimed and is returned to dump. Magnetic separation can increase the consumer properties of the slag screening, but it is only magnetic product that is returned to the processing while the mineral part is left in the dump. Basic characteristics of 0–10 mm fraction quoted. It was determined by laboratory study, that after extraction of ferromagnetic inclusions, the true screening density decreased by 17.5% and bulk density – by 3.1%. The powder-like inclusions remain in the screening, that does not allow to consider the material as a filler for concrete and macadam-sand mixture for road-building. To recycle the magnetic product, extracted out of the screening, decreasing of slagging is needed, as well as systematic evaluation of sulphury inclusion content in it. It was proposed to divide the slag screening for macadam and sand fractions after maximum possible removal magnetic inclusions and powder-like inclusions. It will allow to return into the utilization a part of iron previously lost with the fraction 0–10 mm and to obtain an iron concentrate for sintering. The remained tails in the form of macadam of 5–10 mm fraction, sand 0–5 mm and meliorant with decreased iron content can be used in construction industry and agriculture. By field tests it was determined, that adding meliorants, which contain a grinded screening with oxides of magnesium, phosphor and microelements, into soil, results in increasing crop capacity of vegetables by 30% at test areas.
12
Bedrunka, Dawid, Katarzyna Buchta, Patryk Szary, Katarzyna Maniakowska, Pawel Kiper, Anna Rutkowska, and Sebastian Rutkowski. "The effect of virtual reality exercise on physical fitness." Rehabilitacja Medyczna 23, no. 2 (August 26, 2019): 4–9. http://dx.doi.org/10.5604/01.3001.0013.3717.
Full textAbstract:
Introduction: The aim of this study was to assess physical fitness (PF) in healthy volunteers using the Senior Fitness Test (SFT) after a series of training sessions in virtual reality (VR) using the X-box 360 Kinect System. Materials and methods: This pilot study consisted of 32 healthy subjects aged 19 to 24 years (12 males and 20 females) with the mean age of 20.6±1.4 years and the mean BMI of 23.29±2.3. The subjects participated in the study for 2 weeks, at a frequency of 4 sessions weekly. Each session comprised 4 Kinect Adventures games: 20 000 Leaks, Curvy Creak, Rally Ball and Reflex Ridge. The Senior Fitness Test was used to assess physical fitness. Results: Analysis of data showed improvement in Arm-Curl (30.0 repetitions (rep.)) vs. 35.8 rep., p<0.001), Chair Stand (26.6 rep. vs. 30.2 rep., p<0.001), Back Scratch (3.1 cm vs. 6.1 cm, p<0.033), Chair Sit-and-Reach (1.0 cm vs. 5.3 cm, p<0.001), Up-and-Go (3.5 sec. vs. 3.2 sec., p<0.001) and 6-Minute Walk Test (731.3 m vs. 747.8.m, p<0.220). Statistically significant improvement was noted in 5 out of 6 STF trials. Only the 6-Minute Walk test results were not statistically significant. Conclusions: Training using a console with the Kinect motion sensor had positive effects on the physical fitness of the healthy volunteers.
13
NESWALD, ELIZABETH. "OLIVER HOCHADEL, Öffentliche Wissenschaft. Elektrizität in der deutschen Aufklärung. Göttingen: Wallstein Verlag, 2003. Pp. 364. ISBN 3-89244-629-6. € 35.00 (paperback)." British Journal for the History of Science 39, no. 1 (February 23, 2006): 133–34. http://dx.doi.org/10.1017/s0007087406307893.
Full text
14
Cherpitel, Cheryl J., Yu Ye, and Maristela G. Monteiro. "Dose–Response Relative Risk of Injury From Acute Alcohol Consumption in 22 Countries: Are Women at Higher Risk Than Men?" Alcohol and Alcoholism 54, no. 4 (March 11, 2019): 396–401. http://dx.doi.org/10.1093/alcalc/agz018.
Full textAbstract:
Abstract Aims The risk of injury from alcohol consumption was analyzed by gender, controlling for frequency of heavy drinking occasions, and by cause of injury (traffic, violence, fall, other). Methods Case-crossover analysis was conducted on 18,627 injured patients arriving at the emergency department (ED) within six hours of the event. Findings Risk of injury was similar for females and males at ≤3 drinks prior to injury (OR = 2.74 vs. 2.76, respectively). At higher volume levels females were at greater risk than males, and significantly so at 3.1–6 drinks and 6.1–10 drinks (gender by volume interaction: OR = 0.60, CI = 0.39–0.93 and OR = 0.50, CI = 0.27–0.93, respectively). For those reporting 5+ ≥ monthly, females were at higher risk than males at all volume levels, and the gender by volume interaction was stronger than for those consuming 5+ <monthly at ≤3 drinks (OR = 0.51, CI = 0.28–0.92) and 6.1–10 drinks (OR = 0.39, CI = 0.18–0.82). Females were at higher risk of injury than males for all causes of injury except those related to traffic at lower levels of consumption (<6 drinks), although the gender by volume interaction was significant only for injury from other causes at 3.1–6 drinks (OR = 0.23, CI = 0.09–0.87). Conclusions Females are at higher risk of injury than males, regardless of frequency of heavy drinking and for all causes other than those related to traffic.
15
Uslu, S., G. Kabadayi, P. Teke Kisa, T. Yüce İnel, Z. Arslan, N. Arslan, S. Akar, F. Onen, and İ. Sari. "SAT0543 PREVALENCE OF FABRY’S DISEASE IN MILD AND SEVERE FMF PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1228.2–1229. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5903.
Full textAbstract:
Background:Fabry disease (FD) is a rare metabolic disorder caused by the mutations in the α-galactosidase A (GLA) gene. FD patients present with heterogeneous clinical manifestations, which may overlap with systemic diseases including familial Mediterranean fever (FMF). Recurrent episodes of fever, abdominal pain, and arthralgias can be observed in both disorders and this may lead to misdiagnosis.Objectives:To investigate FD prevalence in mild and severe FMF patients.Methods:A total of 66 FMF patients, according to the Tel-Hashomer criteria, were included in the study. Patients were grouped into mild (Group 1) and severe (Group 2) subsets according to the severity score. α-GLA enzyme activity and mutations in the GLA gene were performed. Demographic features, clinical findings, MEFV mutations and treatments were recorded.Results:The clinical and demographical characteristics of the patients were given in Table 1. In severe form, 27 patients were using biological drug and 40.7% had amyloidosis. Symptoms related to FD including hypohidrosis, acroparesthesias, and painful neuropathies, were not different between the groups. Only one patient in group 1 had a low GLA enzyme activity (0.1 nmol/h/ml;Normal >2.5) which also had mutations in the GLA gene but MEFV mutation test was negative. (Table 2). This patient was a 39-year-old female with recurrent abdominal pain, distal extremity pain and the presence of fever during the attacks. She was heterozygous for R301Q. In detailed history, she reported mild acroparesthesias, hypohidrosis, and tinnitus.Table 1.Demographic and clinical findingsAll patientsn: 66Group 1n: 32Group 2n: 34p-valueAge, median (min./max.)34 (17/64)27 (17/59)36 (18/64)0.192Male, n (%)36 (54.5)14 (43.8)22 (64.7)0.137Disease duration, median (min./max.)20.5 (1/57)12.5 (2/50)25 (1/57)0.006Family history of FMF, n (%)41 (62.1)22 (68.8)19 (57.6)0.443Alpha-galactosidase A (nmol/h/ml), median (min./max.)5.9 (0.1/16)5.6 (0.1/9.6)6 (3.1/16)0.330Abdominal pain, n (%)58 (87.9)31 (96.9)27 (79.4)0.030Fever, n (%)54 (81.8)25 (78.1)29 (85.3)0.532Arthritis, n (%)34 (51.5)10 (31.3)24 (70.6)0.003Pleuritis, n (%)31 (47)19 (59.4)12 (35.3)0.083Painful neuropathy, n (%)23 (34.8)13 (40.6)10 (29.4)0.440Acroparesthesias, n (%)9 (13.6)6 (18.8)3 (8.8)0.240Angiokeratomas, n (%)0 (0)0 (0)0 (0)-Cardiac abnormalities1 (1.5)1 (3,1)0 (0)0.485Tinnitus, n (%)4 (6.1)3 (9.4)1 (2.9)0.274Hearing loss, n (%)2 (3)2 (6.2)00.086Hypohydrozis, n (%)2 (3)1 (3.1)1 (2.9)0.965Cornea verticillata, n (%)0 (0)0 (0)0 (0)-Proteinüria, n (%)13 (19.7)2 (6.3)11 (32.4)0.012Colchine dosing (mg/day), median (min./max.)2 (1/3)1 (1/2)2 (1/3)<0.001Table 2.MEFV mutant alleles and GLA mutationsAll patientsn: 66Group 1n: 32Group 2n: 34Alpha -galactosidase A (GLA) gene mutations, n (%)1 (1.5)1 (3.1)0 (0)M694V mutations, n (%)47 (35.6)17 (26.5)30 (44.1)Non-M694V mutations, n(%)36(27.2)20 (31.2)16 (23.5)Conclusion:In this study, we showed the following: 1) the FD rate in the total FMF group was 1.5% (3.1% in group 1), 2) none of the patients in the severe FMF subset had abnormal enzyme activity or mutations related with FD, 3) symptoms related with FD such as hearing loss, hypohidrosis, acroparesthesias, and painful neuropathies also noted in FMF patients particularly in the milder group. Based on our results, FD should be considered in the differential diagnosis of FMF particularly in patients with atypical symptoms.Disclosure of Interests:None declared
16
Strati, Gina L., Julious L. Willett, and Frank A. Momany. "A DFT/ab initio study of hydrogen bonding and conformational preference in model cellobiose analogs using B3LYP/6-311++G**." Carbohydrate Research 337, no. 20 (November 2002): 1851–59. http://dx.doi.org/10.1016/s0008-6215(02)00269-0.
Full text
17
Lefferts, Elizabeth C., Joseph M. Saavedra, Bong Kil Song, and Duck-chul Lee. "Effect of the COVID-19 Pandemic on Physical Activity and Sedentary Behavior in Older Adults." Journal of Clinical Medicine 11, no. 6 (March 12, 2022): 1568. http://dx.doi.org/10.3390/jcm11061568.
Full textAbstract:
Whether the COVID-19 pandemic has long-lasting effects on physical activity (PA) and sedentary behavior in the vulnerable older adult population is uncertain. A total of 387 older adults (75 ± 6 years) completed a retrospective questionnaire on time spent sitting, walking, and performing aerobic and muscle-strengthening PA before, during the first three months, and one year into the COVID-19 pandemic. Whether the participants met the aerobic and muscle-strengthening PA guidelines was then determined. Of the 387 older adults, 376 (97%) were vaccinated. The participants completed 361 ± 426, 293 ± 400, and 454 ± 501 min/week of moderate-to-vigorous aerobic PA before, during the first three months, and one year into the pandemic, respectively. During the same time periods, the participants performed muscle-strengthening PA 87 ± 157, 68 ± 163, and 90 ± 176 min/week, walked 2.4 ± 1.7, 2.3 ± 1.7, and 2.6 ± 1.9 h/day, and sat 6.2 ± 2.9, 7.4 ± 3.1, and 6.1 ± 2.9 h/day, respectively. Aerobic PA, muscle-strengthening PA, and walking time decreased, whereas sitting time increased, during the first three months of the pandemic (p < 0.05), and then returned to pre-pandemic levels after one year (p < 0.05). The percentage of participants meeting both aerobic and muscle-strengthening PA guidelines decreased during the first three months of the pandemic (48.9% to 33.5%, p < 0.001), but returned to pre-pandemic levels one year later (p < 0.001). In conclusion, the COVID-19 pandemic significantly decreased PA and increased sitting time in older adults; however, both PA and sitting time returned to pre-pandemic levels after one year.
18
Newaz, Md Mehedi, Avijit Kumar Sikder, and Faruquzzaman. "Comparison of the outcome of management of congenital idiopathic clubfoot treated by ponseti method with modified technique." Bangladesh Medical Journal Khulna 52, no. 1-2 (March 26, 2020): 7–11. http://dx.doi.org/10.3329/bmjk.v52i1-2.46141.
Full textAbstract:
Background: Ponseti's technique has become the standard and most effective treatment modality for correction of Congenital Talipes Equinovarus (CTEV) in newborn. With time, little modification has been done in the classic technique.
Objective: Our objective in this study was to compare the outcome in the recent years (modified Ponseti technique) with the results of our previous study (classic Ponseti technique).
Methods: A total number of 976 patients (1553 feet) of Congenital Talipes Equino Varus were treated from October 2009 to February 2019 in Khulna Medical College Hospital and in private hospitals. In this retrospective study (based on convenient sampling), there were two groups. In group A, a total 621 patients (with a total 1033 feet) were treated from October 2009 to August, 2015. In group B, 355 patients (520 feet) were treated from November 2015 to February 2019.
Results: In this study, in group A, approximately 88.6% was in 0-6 months age group. 64.9% was male patients. 3.7% patients had positive family history. In group B, majority of the patients (301, 84.8%) was in 0-6 months age group. 211 patients (59.4%) was male child. In approximately 3.1% (11) patients family history was positive. Approximately in 95.9% (991 out of total 1033) and 96.5% (502 out of total 520) feet respectively in group A and B, tenotomy was required. Dropout rates were 7.6% and 4.1% in respective groups. Minor bleeding was observed in approximately 1.5% (15) and 1.4% (7) feet in respective groups, followed by plaster related complications in approximately 2.2% (23) and 1.0% (5) feet in group A and B. Patients' compliance was found significantly higher in group B in contrast to group A. In group B, it was over 90%, whereas in group A, it was approximately 64.1 %.
Conclusion: The ultimate outcome of Ponseti repair is improving by less requirement of total number of plaster, resistant cases and reduction in overall dropout rate by the newer modification.
Bang Med J (Khulna) 2019; 52 : 7-11
19
Kshivets, Oleg. "Lymph node metastases of gastric cancer and blood cell circuit." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e16024-e16024. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e16024.
Full textAbstract:
e16024 Background: Significance of blood cell circuit in terms of detection of gastric cancer (GC) patients (GCP) with lymph node metastases was investigated. Methods: We analyzed data of 793 consecutive GCP (age = 57±9.4 years; tumor size = 5.4±3.1 cm) radically operated (R0) and monitored in 1975-2021 (m = 555, f = 238; distal gastrectomies = 460, proximal gastrectomies = 163, total gastrectomies = 170, combined gastrectomies with resection of pancreas, liver, diaphragm, colon transversum, esophagus, duodenum, splenectomy, small intestine, kidney, adrenal gland = 244; D2-lymphadenectomy = 513, D3-4 = 280; T1 = 235, T2 = 220, T3 = 182, T4 = 156; N0 = 433, N1 = 109, N2 = 251; G1 = 222, G2 = 162, G3 = 409; early GC = 162, invasive = 631; only surgery = 621, adjuvant chemoimmunotherapy-AT = 172 (5-FU+thymalin/taktivin). Variables selected for study were input levels of blood cell circuit, sex, age, TNMG. Differences between groups were evaluated using discriminant analysis, clustering, nonlinear estimation, structural equation modeling, Monte Carlo, bootstrap simulation and neural networks computing. Results: It was revealed that separation of GCP with lymph node metastases (n = 360) from GCP without metastases (n = 433) significantly depended on: eosinophils (%, abs, total), thrombocytes (abs, total), ESS, Hb, erythrocytes (abs), residual nitrogen, protein, cell ratio factors (CRF) (ratio between cancer cells- CC and blood cells subpopulations), T, G, tumor size, histology, tumor growth, blood group, procedures type (P = 0.043-0.000). Neural networks computing, genetic algorithm selection and bootstrap simulation revealed relationships of lymph node metastases and CRF: thrombocytes/CC (rank = 1), healthy cells/CC (2), erythrocytes/CC (3), monocytes/CC (4), segmented neutrophils/CC (5), lymphocytes/CC (6), leucocytes/CC (7), eosinophils/CC (8), stick neutrophils/CC (9). Correct classification N0—N12 was 99.9% by neural networks computing (area under ROC curve = 1.0; error = 0.0). Conclusions: Lymph node metastases of gastric cancer significantly depended on blood cell circuit.
20
Siitonen, Juha. "Faunistic records of Carabidae and Staphylinidae (Coleoptera) caught by pitfall trapping in western Finnish Lapland." Entomologica Fennica 4, no. 4 (December 1, 1993): 225–31. http://dx.doi.org/10.33338/ef.83774.
Full textAbstract:
New faunistic records are given based on a total collection of 41 601 Coleoptera, of which 6 364 are Carabidae and 30 414 Staphylinidae. They were collected mostly by pitfall trapping in different forest and mire habitats in western Finnish Lapland. A total of 52 carabid and 186 staphy linid species are reported. Of these, 6 (11 %) and 49 (26 %) species, respectively, were new for the province Lapponia kemensis occidentalis (LkW). Microdota wireni Brundin is reported as new for Finland. Notes on the occurrence and biology of the following species are given: Platynus (Agonum) mannerheimii, Harpalus nigritarsis, Philonthus lederi, Lesteva monticola, Oxypoda operta, Mocyta (A theta) amblystegii, Lomechusa pubicollis and Myllaena hyperborea.
21
Bali, Rajandeep Singh, Rajni ., Yawar Watali, Shyam Kumar Gupta, and Geetanjali Gupta. "Evaluating serum bilirubin levels in acute appendicitis and appendiceal perforation." International Journal of Research in Medical Sciences 8, no. 3 (February 26, 2020): 859. http://dx.doi.org/10.18203/2320-6012.ijrms20200559.
Full textAbstract:
Background: Acute appendicitis is one of the commonest surgical emergencies. Authors undertook this study to evaluate serum bilirubin levels in acute appendicitis and appendiceal perforation.Methods: A retrospective study evaluating the serum bilirubin levels in acute appendicitis and appendiceal perforation was carried out for 6 years at three tertiary care hospitals at India from 2014 to 2019. Patients having acute appendicitis and appendiceal perforation, confirmed on histopathology, with no other medical or surgical comorbidity were included in the study.Results: The total number of our study subjects was 927. 306 patients had appendiceal perforation, amongst these, 226 (74%) had hyperbilirubinemia. Out of the 621 patients having acute appendicitis only 186 (30%) had hyperbilirubinemia. The lowest and the highest serum bilirubin levels of this study group were 0.6 and 3.1 mg/dl, respectively, with an average of 1.6 mg/dl. In patients diagnosed to be having acute appendicitis, the lowest and highest serum bilirubin levels were 0.6 and 2.4 mg/dl, respectively, with an average of 1.3 mg/dl. As for the patients having appendiceal perforation the lowest and highest serum bilirubin levels were 0.8 and 3.1 mg/dl, respectively, with an average of 1.8 mg/dl.Conclusions: Hyperbilirubinemia is seen in acute appendicitis but predominantly in appendiceal perforation, so serum bilirubin estimation may help us in diagnosing appendiceal perforation pre-operatively if and when used in conjunction with other available diagnostic modalities.
22
Захарова, Лариса Александровна, and А. Д. Ибатов. "Effectiveness of drug and non-drug treatment of tobacco dependence among physicians and nurses." Hygiene and sanitation 99, no. 4 (May 26, 2020): 390–93. http://dx.doi.org/10.47470/0016-9900-2020-99-4-390-393.
Full textAbstract:
Introduction. The article is devoted to assessing the effectiveness of drug and non-drug treatment of tobacco dependence in health care workers. Material and methods. The study included 621 medical workers (237 men and 384 women) working in hospitals in Moscow, at the average age of 48.3 ± 5.6 years, including 207 doctors and 414 nurses. The medical workers were divided into 2 groups depending on the anti-smoking program used. The first group consisted of 316 medical workers who received non-drug methods of treatment: psychosocial support, using cognitive aspects; psychotherapy; breathing exercises; acupuncture; increase physical activity. The second group consisted of 305 medical workers who, in addition to non-drug methods (described above), received Varenicline treatment (Champix® - tablets) and, if necessary, nicotine replacement therapy. Results. In medical workers from the 2nd group, besides non-pharmacological therapy, received the drug Varenicline, 195 out of 305 (64%) persons completely stopped smoking; In the 1st group of Medical workers receiving non-drug therapy, 177 out of 316 (56% ) cases completely quit smoking (OR= 1.40; 95% CI: 1.01-1.93; p=0.0423). 6 months after the end of the treatment program, in the first group 84 (26.7%) medical workers) in the 2nd group - 31 medical workers (10.2%) restarted smoking, (OR=3.02, 95% CI: 2.05-5.02; p<0.00001). Conclusion. Thus, the antismoking program, including drug Varenicline and, if necessary, nicotine-replacement therapy, as well as non-drug effects, including psycho-social support; psychotherapy; breathing exercises; acupuncture; an increase in physical activity showed higher efficacy compared with the antismoking program without Varenicline, moreover, high efficacy remained even after the treatment carried out for 6 months.
23
Zakharova, Larisa A., and A. D. Ibatov. "Effectiveness of drug and non-drug treatment of tobacco dependence among physicians and nurses." Hygiene and sanitation 99, no. 4 (May 26, 2020): 390–93. http://dx.doi.org/10.33029/0016-9900-2020-99-4-390-393.
Full textAbstract:
Introduction. The article is devoted to assessing the effectiveness of drug and non-drug treatment of tobacco dependence in health care workers. Material and methods. The study included 621 medical workers (237 men and 384 women) working in hospitals in Moscow, at the average age of 48.3 ± 5.6 years, including 207 doctors and 414 nurses. The medical workers were divided into 2 groups depending on the anti-smoking program used. The first group consisted of 316 medical workers who received non-drug methods of treatment: psychosocial support, using cognitive aspects; psychotherapy; breathing exercises; acupuncture; increase physical activity. The second group consisted of 305 medical workers who, in addition to non-drug methods (described above), received Varenicline treatment (Champix® - tablets) and, if necessary, nicotine replacement therapy. Results. In medical workers from the 2nd group, besides non-pharmacological therapy, received the drug Varenicline, 195 out of 305 (64%) persons completely stopped smoking; In the 1st group of Medical workers receiving non-drug therapy, 177 out of 316 (56% ) cases completely quit smoking (OR= 1.40; 95% CI: 1.01-1.93; p=0.0423). 6 months after the end of the treatment program, in the first group 84 (26.7%) medical workers) in the 2nd group - 31 medical workers (10.2%) restarted smoking, (OR=3.02, 95% CI: 2.05-5.02; p<0.00001). Conclusion. Thus, the antismoking program, including drug Varenicline and, if necessary, nicotine-replacement therapy, as well as non-drug effects, including psycho-social support; psychotherapy; breathing exercises; acupuncture; an increase in physical activity showed higher efficacy compared with the antismoking program without Varenicline, moreover, high efficacy remained even after the treatment carried out for 6 months.
24
Johnson, Bruce E., Mark G. Kris, Lynne D. Berry, David J. Kwiatkowski, Anthony John Iafrate, Marileila Varella-Garcia, Ignacio Ivan Wistuba, et al. "A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC)." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 8019. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.8019.
Full textAbstract:
8019 Background: The detection of driver mutations in the EGFR and ALK genes and targeted therapy has transformed treatment of lung cancer. The LCMC was established in 2009 to assay lung adenocarcinomas for driver genomic alterations in 10 genes and to study and treat patients by their molecular subtypes. Methods: The 14-member LCMC enrolled patients with metastatic adenocarcinoma of the lung and tested their tumors in CLIA laboratories for KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, and NRAS mutations using multiplexed assays, and for ALK rearrangements and MET amplifications using fluorescence in situ hybridization (FISH). Results: 1,102 eligible patients were enrolled; 1,007 underwent testing for at least one genomic alteration with 733 undergoing testing for all 10 genes. 600 patients were women (60%) with a median age of 63; 341 were never smokers (34%) and 589 former smokers (58%). A driver alteration was detected in 622 (62%) of the 1,007 with any genotyping, and in 465 (63%) of the 733 fully genotyped cases. Among the tumors with full genotyping, drivers were found as follows: KRAS 182 (25%), sensitizing EGFR 107 (15%), ALK rearrangements 56 (8%), other EGFR 43 (6%), two genes 29 (4%), BRAF 16 (2%), HER2 15 (2%), PIK3CA 6 (1%), MET amplification 5 (1%), NRAS 5 (1%), MEK1 1 (<1%), and AKT1 0 (0%). Results were used to select targeted therapy or targeted trials in 279 patients with a driver alteration (28% of 1,007 total). Among 938 patients with clinical follow-up and treatment information, 264 with a driver alteration treated with a targeted agent had a median survival of 3.5 years; 313 with a driver who did not receive targeted therapy had a median survival of 2.4 years; while 361 without an identified driver had a median survival of 2.1 years (p<0.0001). Conclusions: An actionable driver alteration was detected in 62% of tumors from patients with lung adenocarcinomas, leading to use of a targeted therapy in 28%. The patients with an identified driver treated with a targeted agent lived longer than those patients who did not receive targeted therapy. Multiplexed genomic testing can aid physicians in matching patients with targeted treatments and appropriate clinical trials.
25
Anashkin, S., A. Bovkun, L. Bindi, V. Garanin, and Y. Litvin. "Kudryavtsevaite, Na3MgFe3+Ti4O12, a new kimberlitic mineral." Mineralogical Magazine 77, no. 3 (April 2013): 327–34. http://dx.doi.org/10.1180/minmag.2013.077.3.06.
Full textAbstract:
AbstractKudryavtsevaite, ideally Na3MgFe3+Ti4O12, is a new mineral from kimberlitic rocks of the Orapa area, Botswana. It occurs as rare prismatic crystals, up to 100 μm m across, associated with Mg-rich ilmenite, freudenbergite and ulvöspinel. Kudryavtsevaite is opaque with a vitreous lustre and shows a black streak. It is brittle; the Vickers hardness (VHN100) is 901 kg mm−2 (range: 876–925) (Mohs hardness ∼6). In reflected light, kudryavtsevaite is moderately bireflectant and very weakly pleochroic from dark grey to a slightly bluish grey. Under crossed polars, it is very weakly anisotropic with greyish-bluish rotation tints. Internal reflections are absent. Reflectance values (%), Rmin and Rmax, are: 21.3, 25.4 (471.1 nm), 20.6, 24.1 (548.3 nm), 20.0, 23.5 (586.6 nm) and 19.1, 22.4 (652.3 nm).Kudryavtsevaite is orthorhombic, space group Pnma, with a = 27.714(1), b = 2.9881(3), c = 11.3564(6) Å, V = 940.5(1) Å3, and Z = 4. The crystal structure [R1 = 0.0168 for 819 reflections with I > 2σ(I)] consists of edge-sharing and corner-sharing chains composed of Mg, Fe3+ and Ti atoms coordinated by six atoms of oxygen and running along the b axis, with Na filling the tunnels formed by the chains. The eight strongest powder-diffraction lines [d in Å (I/I0) (hkl)] are: 7.17 (100) (301), 4.84 (70) (302), 2.973 (35) (901), 2.841 (50) (004), 2.706 (50) (902), 2.541 (50) (312), 2.450 (70) (611), and 2.296 (45) (612). The average results of 12 electron microprobe analyses gave (wt.%): Na2O 16.46(15), CaO 1.01(3), MgO 5.31(5), Fe2O3 22.24(32), Cr2O3 1.05(6), Al2O3 0.03(2), TiO2 53.81(50), total 99.91, corresponding to the empirical formula (Na2.89Ca0.10)Σ2.99(Ti3.67Fe1.523+Mg0.72Cr0.08)Σ5.99O12, or ideally Na3MgFe3+Ti4O12.The new mineral has been approved by the IMA-CNMNC and named for Galina Kudryavtseva (1947–2006), a well known Russian mineralogist and founder of the Diamond Mineralogy Laboratory and scientific school for investigation of diamond mineralogy and geochemistry at the Lomonosov State University in Moscow, Russia.
26
Xu, Min, Bai Sheng Ye, and Qiu Dong Zhao. "Terrestrial Water Storge Changes in the Tangnaihai Basin Measured by GRACE during 2003-2008, China." Applied Mechanics and Materials 316-317 (April 2013): 520–26. http://dx.doi.org/10.4028/www.scientific.net/amm.316-317.520.
Full textAbstract:
Abstract.The amount of water storage change in Tangnaihai basin is obtained by using monthly gravity field data, which is derived from GRACE satellite between 2003 and 2008, with Gaussian filter. Combined with the same time period monthly precipitation data of the regional meteorological stations, we analysis spatial-temporal variation trend of water storge change in Tangnaihai basin for nearly 6 years. Results show that the spatial distribution of water storge change in Tangnaihai basin has obvious difference,water storge change is more in west than in east area.Water storge change has obviously seasonal variation change, and it has the same process with precipitation.The trend of water storge change increase in annual in study area. Water storge change increased from 2003 to 2008 in totally in Tangnaihai basin.The average rate is 0.5 mm/month,and water storge change reduced about 6.1*106 m3.
27
Egorova, Svetlana A., Lidiya A. Kaftyreva, Lyudmila V. Suzhaeva, Anna V. Zabrovskaia, Elena V. Voitenkova, Zoya N. Matveeva, Yulia V. Ostankova, et al. "ANTIMICROBIAL RESISTANCE AND CLINICAL SIGNIFICANT RESISTANCE MECHANISMS OF SALMONELLA ISOLATED IN 2014-2018 IN ST.PETERSBURG, RUSSIA." Russian Clinical Laboratory Diagnostics 64, no. 10 (October 15, 2019): 620–26. http://dx.doi.org/10.18821/0869-2084-2019-64-10-620-626.
Full textAbstract:
The article presents the results of antimicrobial resistance monitoring of Salmonella isolated from children and adults with diarrhea in St. Petersburg in 2014-2018. In 746 isolates of 42 serovars more than 90,0% belonged to three: S. enteritidis (79,6%), S. typhimurium (6,8%) and S. infantis (3,8%). The antimicrobial susceptibility testing (according the EUCAST) to 7 classes of antimicrobials revealed the resistance in 78,6% of Salmonella. Low-level quinolone resistance (MIC of ciprofloxacin 0,12-0,5 mg/l) was detected in 63,3% isolates (S. enteritidis -71,0%, S. typhimurium - 15,7%, S. infantis - 89,3%) and was due to five kinds of single nucleotide substitutions in gyrA: Asp87Tyr - 36,1% of studied isolates (only S. infantis); Ser83Phe - 22,2% (only S. enteritidis); Asp87Asn - 19,4% (S. enteritidis, S. typhimurium, S. hadar, S. newport); Ser83Tyr -11,1% (S. enteritidis and S. infantis) and Asp87Gly - 8,3% (only S. enteritidis). Only in one S. kentucky isolate with high-level fluoroquinolone resistance (MIC of ciprofloxacin > 8,0 mg/l) two substitutions (Ser83Phe and Asp87Asn) were detected. Two Salmonella isolates (S. typhimurium and S. corvallis) had plasmid-mediated quinolone resistance (qnrS). Extended-spectrum cephalosporin resistance was found in 6 Salmonella serovars (1,6%). The bla-genes were detected: of genetic group CTX-M1 - in 10 isolates (serovars S. typhimurium, S. enteritidis, S. abony, S. coeln and S. virchow), CTX-M2 - in 2 S. typhimurium isolates, CTX-M9 - in three S. enteritidis isolates. In one S. typhimurium CTX-M1 and CTX-M2 were detected. The gene of CMY-2 (molecular class C cephalosporinase) was revealed in two isolates (S. newport and S. enteritidis). Our study showed that Salmonella (the main bacterial pathogen of acute diarrhea in children and adults) isolated in Saint-Petersburg had antimicrobial resistance to drugs of choice for salmonellosis treatment.
28
Pang, Hui, Wen Guan Zhang, and Sheng Min Zhao. "Non-Dopant Electroluminescent Devices Based on Benzoxazinone Derivative as Strong Fluorescence in Solid Film." Advanced Materials Research 399-401 (November 2011): 1151–55. http://dx.doi.org/10.4028/www.scientific.net/amr.399-401.1151.
Full textAbstract:
The orange fluorescent compound 2-[2-(p-toluenesulphonylamino)-5-chlorophenyl]-6- chloro-4H-3,1-benzoxazin-4-one (Cl-TSB) was synthesized by reacting 2-amino-5-chlorobenzoic acid with p-toluenesulphonyl chloride. The strong photoluminescent peak was at 544 nm in solid film. HOMO and LUMO energy levels were calculated -5.00 and -1.82 eV. The multilayer organic light-emitting devices (OLEDs) ITO/NPB/Cl-TSB/BCP/TPBi or Alq3/LiF/Al were fabricated. The electroluminescent peaks of all devices were at ca. 620 nm with luminance of over 100 cd/m2. The characteristics of devices demonstrated that Cl-TSB was an orange emitter suitable for OLED.
29
Cuartero, M., A. J. Betbesé, K. Núñez, J. Baldirà, and J. Ordonez-Llanos. "Does Whole-Blood Neutrophil Gelatinase-Associated Lipocalin Stratify Acute Kidney Injury in Critically Ill Patients?" Disease Markers 2019 (May 2, 2019): 1–9. http://dx.doi.org/10.1155/2019/8480925.
Full textAbstract:
Purpose. To analyse the capacity of whole-blood NGAL (wbNGAL) to stratify AKI in critically ill patients with and without sepsis. Methods. Whole-blood NGAL was measured with a point-of-care device at admission and 48 hours later in patients admitted to a general ICU. Patients were classified by the AKIN and KDIGO classifications at admission and 24 and 48 hours. We performed an ROC curve analysis. wbNGAL values at admission were compared in patients with sepsis and septic shock. Results. The study included 100 consecutively admitted patients (40 female) with mean age 59.1±17.8 years. Thirty-three patients presented AKI at admission, and 10 more developed it in the next 48 h. Eighteen patients had AKI stage 3, 14 of them at admission. Nine patients required renal replacement therapy. According to KDIGO at admission, wbNGAL values were 78 μg/L (60-187) in stage 0 (n=67), 263 μg/L (89-314) in stage 1 (n=8), 484 μg/L (333-708) in stage 2 (n=11), and 623 μg/L (231-911) in stage 3 (n=14), p=0.0001 for trend. Ten patients did not complete 48 hours of study: 6 of 10 were discharged (initial wbNGAL 130 μg/L (60-514)) and 4 died (773 μg/L (311-1010)). The AUROC curve of wbNGAL to predict AKI was 0.838 (95% confidence interval 0.76-0.92, p=0.0001), with optimal cut-off value of 178 μg/L (sensitivity 76.7%, specificity 78.9%, p<0.0001). At admission, twenty-nine patients had sepsis, of whom 20 were in septic shock. wbNGAL concentrations were 81 μg/L (60-187) in patients without sepsis, 481 (247-687) in those with sepsis, and 623.5 μg/L (361-798) in the subgroup of septic shock (p<0.0001). Conclusions. Whole-blood NGAL concentration at ICU admission was a good stratifier of AKI in critically ill patients. However, wbNGAL concentrations were higher in septic patients irrespective of AKI occurrence.
30
Melcher, D. H. "Exfoliative cytopathology. (3rd Edition) Z. M. Naib. Little, Brown & Co. Boston & Toronto 1985. No. of pages: XI + 629. Price: £47.50 ISBN: 0 316 59673 6." Journal of Pathology 150, no. 4 (December 1986): 296. http://dx.doi.org/10.1002/path.1711500413.
Full text
31
Gardien, Véronique, Olivier Vanderhaeghe, Nicolas Arnaud, Alain Cocherie, Marion Grange, and Christophe Lécuyer. "Thermal maturation and exhumation of a middle orogenic crust in the Livradois area (French Massif Central)." Bulletin de la Société Géologique de France 182, no. 1 (January 1, 2011): 5–24. http://dx.doi.org/10.2113/gssgfbull.182.1.5.
Full textAbstract:
AbstractUpper Carboniferous heating and melting of the middle orogenic crust associated with the emplacement of syntectonic granitoids are documented in the Upper Gneissic Unit of the Livradois area (central part of the French Massif Central). Crustal melting post-dates peak metamorphism conditions (800-625°C, 10-8 kb) dated at 360 ± 4 Ma (U-Th-Pb on monazite). The P-T evolution of the metamorphic series indicates that Barrovian metamorphism was followed by a decompression (from 10 ± 1 kbar to 6 ± 1 kbar) associated with either a decrease in temperature in the southern part of the series or with an increase in temperature (of about 150°C) in the northern part of the series. This evolution records the first step of the exhumation of the series coeval with granitoids intrusion, of which the emplacements were dated at 315 ± 4 and 311 ± 18 Ma (U-Pb on zircon). The final stage of the exhumation is associated with an isobaric cooling of the whole series. Similarity of 40Ar/39Ar ages for biotite in the paragneisses (307-300 Ma) and K-feldspar in the granitoids (306-300 Ma) document rapid cooling for this stage. Moreover dextral reverse mylonites, at the border and the northern part of the metamorphic series indicate north-south compression coeval with the unroofing of the series. Youngest 40Ar-39Ar ages on K-feldspar (274.6 ± 5 Ma) combined with normal shearing in mylonites limiting the Carboniferous Brassac-les-Mines basin document the late Carboniferous-early Permian stage of extension coeval with the upwelling of the Velay granitic dome.
32
Walz, Lars, Gian M. Salzmann, Thomas Fabbro, Stefan Eichhorn, and Andreas B. Imhoff. "The Anatomic Reconstruction of Acromioclavicular Joint Dislocations Using 2 TightRope Devices." American Journal of Sports Medicine 36, no. 12 (September 2, 2008): 2398–406. http://dx.doi.org/10.1177/0363546508322524.
Full textAbstract:
Background For the reconstruction of acromioclavicular (AC) joint separation, several operative procedures have been described; however, the anatomic reconstruction of both coracoclavicular ligaments has rarely been reported. Purpose The aim of this biomechanical study is to describe a new procedure for anatomic reconstruction of the AC joint. Study Design Controlled laboratory study. Materials and Methods Forty fresh-frozen cadaveric shoulders were tested. Cyclic loading and a load-to-failure protocol was performed in vertical (native, n = 10; reconstructed, n = 10) and anterior directions (native, n = 10; reconstructed, n = 10) on 20 AC joints and repeated after anatomic reconstruction. Reconstruction of conoid and trapezoid ligaments was achieved by 2 TightRope devices (Arthrex, Naples, Florida). Dynamic, cyclic, and static loading until failure in vertical (n = 5) and horizontal (n = 5) directions were tested in native as well as reconstructed joints in a standardized setting. Results The native coracoclavicular ligaments in static load for vertical force measured 598 N (range, 409–687), elongation 10 mm (range, 6–14), and stiffness 99 N/mm (range, 67–130); static load for anterior force was 338 N (range, 186–561), elongation 4 mm (range, 3–7), and stiffness 140 N/mm (range, 70–210). The mean maximum static load until failure in reconstruction for vertical force was 982 N (range, 584–1330) ( P = .001), elongation 4 mm (range, 3–6) ( P < .001), and stiffness 80 N/mm (range, 66.6–105) ( P = .091); and for anterior static force 627 N (range, 364–973) ( P < .001), elongation 6.5 mm (range, 4–10) ( P = .023), and stiffness 78 N/mm (range, 46–120) ( P = .009). During dynamic testing of the native coracoclavicular ligaments, the mean amount of repetitions (100 repetitions per stage, stage 0–100 N, 100–200 N, 200–300 N, etc, and a frequency of 1.5 Hz) in native vertical direction was 593 repetitions (range, 426–683) and an average of 552 N (range, 452–683) load until failure. In vertical reconstructed testing, there were 742 repetitions (range, 488–893) ( P = .222; with a load until failure of 768 N (range, 486–900) ( P = .095). In the anterior direction load, the native ligament failed after an average of 365 repetitions (range, 330–475) and an average load of 360 N (range, 307–411), while reconstructed joints ended in 549 repetitions (range, 498–566) (P = .008J with a load until failure of 547 N (range, 490–585) ( P = .008). In all testing procedures, a preload of 5 N was performed. Conclusion The anatomic reconstruction of the AC joint using TightRope is a stable and functional anatomic reconstruction procedure. The reconstruction technique led to favorable in vitro results with equal or even higher forces than native ligaments. Clinical Relevance Through anatomic repair, stable function of the AC joint can be achieved in an anatomic manner.
33
O'Reilly, Eileen Mary, Do-Youn Oh, Neesha Dhani, Daniel John Renouf, Myung Ah Lee, Weijing Sun, George A. Fisher, et al. "A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study." Journal of Clinical Oncology 36, no. 4_suppl (February 1, 2018): 217. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.217.
Full textAbstract:
217 Background: Durvalumab (D) and tremelimumab (T), monoclonal antibodies against PD-L1 and CTLA-4 immune checkpoints, have shown efficacy as monotherapy/combination therapy in multiple cancer types. Herein, we report a randomized phase 2 study to evaluate efficacy and safety of D monotherapy with or without T (D+T) in previously treated mPDAC. Methods: Part A was a lead-in safety and signal-seeking study with plans to expand to Part B as a nonrandomized or randomized controlled study pending efficacy signal. Eligible pts had progressive disease (PD) following front-line 5-FU- or gemcitabine-based therapy. In Part A, pts were randomized to D (1.5 g IV Q4W) or D+T (D 1.5 g IV + T 75 mg IV Q4W × 4 doses → D 1.5 g IV Q4W) for up to 12 months (mo) or until confirmed PD or unacceptable toxicity. Primary endpoint was investigator-assessed objective response rate per RECIST 1.1. Results: In Part A, 65 pts were randomized to D (n = 33) or D+T (n = 32). Due to a pretreatment death, 64 pts received therapy. Eleven pts (34.4%) in D+T and 10 (31.3%) in D had treatment-related adverse events (trAEs); 7 (22%) in D+T and 2 (6%) in D had grade ≥3 trAEs. Common trAEs: fatigue (12.5%), diarrhea (12.5%), and hypothyroidism (9.4%) in D+T; fatigue (9.4%), diarrhea (6.3%), and pruritus (6.3%) in D. Grade ≥3 trAEs were diarrhea (9.4%), fatigue (6.3%) in D+T and ascites (3.1%), hepatitis (3.1%), and increased lipase (3.1%) in D. In D+T, 3 (9.4%) pts and 1 (3.1%) in D discontinued therapy due to trAEs. No trAEs resulted in death. In D+T, 1 (3.1%) pt had a durable confirmed partial response (PR) > 12 mo and disease control rate (DCR) was 9.4%. In D, 2 (6.1%) pts had unconfirmed PRs, and the DCR was 6.1%. Median PFS in both arms was 1.5 mo, and median OS was 3.1 mo in D+T and 3.6 mo in D. Biomarker analyses (tumor mutation burden, PD-L1 and microsatellite status) are currently being evaluated. Conclusions: Typical safety profiles were observed for D or D+T in mPDAC. Part B was not enrolled as the threshold for efficacy was not met in Part A. D and D+T had modest activity in second-line non-selected mPDAC, underpinning the need for multimodal immune-based combinations to overcome intrinsic resistance in this disease. Clinical trial information: NCT02558894.
34
Bondia-Pons, Isabel, Jordi Mayneris-Perxachs, Lluís Serra-Majem, Ana I. Castellote, Abel Mariné, and M. Carmen López-Sabater. "Diet quality of a population sample from coastal north-east Spain evaluated by a Mediterranean adaptation of the Diet Quality Index (DQI)." Public Health Nutrition 13, no. 1 (June 23, 2009): 12–24. http://dx.doi.org/10.1017/s1368980009990231.
Full textAbstract:
AbstractObjectiveTo assess the adherence to the Mediterranean dietary pattern in the population from a coastal region from north-east Spain and its relationship to diseases, applying the Mediterranean Diet Quality Index (M-DQI) validated by the use of several biomarkers.DesignCross-sectional nutrition survey.SettingPopulation-based random sample derived from the Catalan Nutrition Survey.SubjectsA total of 621 healthy adults.ResultsThe Catalan representative sample presented a mean M-DQI score of 6·6 (sd 2·3, median 7, range 0–14). The percentage of adherence to the Mediterranean diet was 53 %; 10 % of subjects showed high adherence to the Mediterranean diet, while only 2 % were categorized as poorest adherence. The plasma fatty acid profile of the Catalan sample progressed with perfect regularity throughout the index ranges. Both EPA and DHA presented a significant correlation to the M-DQI (r = −0·410 for EPA and −0·360 for DHA). A significant increase in palmitic, oleic and α-linolenic acids and a significant decrease in stearic, linoleic and arachidonic acids content were also observed. The mean values for the M-DQI according to the clinical characteristics of the Catalan sample were also calculated.ConclusionsThe M-DQI has been demonstrated a suitable tool for assessment of an individual’s nutritional status according to the Mediterranean dietary pattern and for clinical purposes. Although the current diet followed in Catalonia seems to agree with the main characteristics of the Mediterranean diet, the promotion of the Mediterranean pattern should be reinforced in the Catalan population, especially among young people.
35
Knights, Francis. "The science of musickeFieldChristopher D. S. and WardhaughBenjamin (eds), John Birchensha: writings on music. Ashgate, Farnham, 2010. Pp. vi + 331, £65.00 (hardback). ISBN 978-0-7546-6213-6." Notes and Records of the Royal Society 65, no. 2 (October 20, 2010): 207–8. http://dx.doi.org/10.1098/rsnr.2010.0088.
Full text
36
Devyatov, A. S. "Long-range Yield of High-density Apple Orchard on Seedling Rootstock." HortScience 31, no. 4 (August 1996): 665d—665. http://dx.doi.org/10.21273/hortsci.31.4.665d.
Full textAbstract:
Apple orchard was planted in 1963 with treatments of 8, 6, or 4 m between rows and 8, 6, 5, 4, 3, and 2 m between trees in the row. Pruning of trees corresponded to the space requirement imposed by each treatment. Spherical canopy seldom formed in treatments of 8 × 2,3,4, or 5 m and the size of canopy was equal to the distance between trees. In treatment of row spacing 6 or 4 m the size of the canopy across the row was 3 or 2 m, respectively, with the length of the canopy equal to the distance between the trees. Tree height was 3 m in all treatments. The cultivar was `Antonovka' on Malus sylvestris rootstock. There were four replications. Fruiting in all treatments begun at the age of 8 years. During the 25 years of productive time of the orchard, there were 7 years without fruit. During the 33 years of orchard operations fruit yield was in treatments (in t·ha–1) 8 × 8 = 301, 8 × 4 = 417, 6 × 3 = 508, 4 × 3 = 612. Yield efficiency, based on crosssection of trunks in 1995 did not depend on orchard density or orchard design.
37
Broliani, Jozélia Nogueira. "Renúncia de receita e a lei de responsabilidade fiscal." A&C - Revista de Direito Administrativo & Constitucional 4, no. 18 (January 18, 2007): 51. http://dx.doi.org/10.21056/aec.v4i18.617.
Full textAbstract:
Introdução - 1 Receitas públicas - Classificação das receitas - Preço público – Tarifa – Pedágio - 2 Receitas tributárias - 2.1 Competência tributária - Espécies tributárias: impostos, taxas, contribuição de melhoria, contribuiçõessociais e empréstimo compulsório (Teoria qüinqüipartite). - 2.2 As receitasconsideradas tributárias na LRF e no âmbito financeiro - 3 Renúncia de receita - 3.1 Anistia - 3.2 Remissão - 3.3 Isenção de caráter não-geral - 3.4 Subsídio - 3.5 Crédito presumido - 3.6 Alteração de alíquota ou modificação da base de cálculo - 3.7 Outros benefícios que correspondam a tratamento diferenciado - 4 Critérios exigidos pela LRF para a renúncia de receita - Renúncia de receita e dívida ativa - Estimativa de impacto orçamentário financeiro - Inclusão da renúncia no planejamento - 5 A renúncia de receita eo ICMS - 6 Conclusões - 6.1 Receita Pública é a entrada definitiva de dinheironos cofres públicos - Referências
38
Farraová, Petra, Marta Ondrejková, and Daniela Demianová. "Transscleral Diode Cyclophotocoagulation in Treatment of Glaucoma." Czech and Slovak Ophthalmology 76, no. 5 (December 20, 2020): 236–42. http://dx.doi.org/10.31348/2020/34.
Full textAbstract:
Cyclodestructive procedures are an alternative of surgical treatment of medically refractory glaucoma. Aim: To assess efficiency and safety of diode cyclophotocoagulation (CPC). Methods: Retrospective study included 81 eyes with advanced glaucoma operated with CPC for elevated intraocular pressure (IOP) from January 2017 to January 2019. CPC was performed in retrobulbar anesthesia with contact diode laser FOX (A.R.C. Laser, Germany) of wavelength 810 nm, transsclerally to the ciliary body. Energy settings: intensity 2 W, exposition time 2 s, 18 applications in arc of 360°. Decrease of intraocular pressure was investigated during month 1, 6 and 12 after CPC. Safety was evaluated according to the best corrected visual acuity (BCVA) on Snellen optotypes and number of postoperative complications. Results: Study on 31 eyes of 24 patients, 21 (68 %) women and 10 (32 %) men, with follow-up during more than 12 months. Mean follow-up time was 19.5 ± 6.1 (from 12 to 29) months. Average age was 75.9 ± 9.2 (56 - 93) years. Indication for CPC was primary open angle glaucoma in 15 eyes (49 %), primary angle closure glaucoma in 6 eyes (19 %) and secondary glaucomas in 10 eyes (32 %). All patients were on therapy of 4 antiglaucomatic drops and 10 of them (32 %) on acetazolamide pills. IOP before CPC was 25.4 ± 11.0 (13–56) mm Hg. After 1 year IOP decreased to 16.9 ± 6.1 (8–40) mm Hg. Best corrected visual acuity (BCVA) before CPC was 0.39 ± 0.34 (0-1), 1 year after CPC 0.36 ± 0.33 (0-1). 1 year after CPC, 11 eyes (35 %) lost 0.23 ± 0.14 rows. 6 from these (19 %) due to other acquired ocular pathologies. Hypotony occurred in 6 % and uveitis in 10 % eyes. Conclusion: CPC is a safe and effective method of lowering IOP.
39
Cheng, W. S. C., S. Roberts, M. Weltman, D. H. G. Crawford, W. Sievert, G. McCaughan, W. Rawlinson, et al. "601 EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 μG/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE 1 PATIENTS WITH CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY." Journal of Hepatology 50 (April 2009): S221. http://dx.doi.org/10.1016/s0168-8278(09)60603-6.
Full text
40
Root, Karen V. "A Primer of Conservation Biology. Fifth Edition. By Richard B. Primack. Sunderland (Massachusetts): Sinauer Associates. $74.95 (paper). xv + 363 p.; ill.; index. ISBN: 978-0-87893-623-6. 2012." Quarterly Review of Biology 89, no. 2 (June 2014): 172. http://dx.doi.org/10.1086/676105.
Full text
41
Albai, Oana, and Romulus Timar. "The Relationship Between 1 Hour Glycemia, During Oral Glucose Tolerance Test and Cardiometabolic Risk." Romanian Journal of Diabetes Nutrition and Metabolic Diseases 19, no. 1 (January 1, 2012): 25–31. http://dx.doi.org/10.2478/v10255-012-0004-6.
Full textAbstract:
The Relationship Between 1 Hour Glycemia, During Oral Glucose Tolerance Test and Cardiometabolic RiskBackground Diabetes mellitus is a very common disease, worldwide there are currently over 366 million diabetics. It seems that people with normal glucose tolerance and blood glucose at 1 hour during OGTT ≥200mg% represent an intermediate phenotype of abnormal glucose metabolism, another disturbance of carbohydrate metabolism that is associated with increased cardiometabolic risk. Objectives Starting from these premises, we decided to analyze the subjects with glucose at 1 hour during OGTT ≥200mg%, but with normal values for fasting glucose and 2 hours glucose. In this subgroup of subjects some parameters of CMR were analyzed. We also performed a comparison of this subgroup of subjects with both normal glucose tolerance and 1-hour glucose <200mg%, and with those with abnormal glucose tolerance. Results According to currently used recommendations to diagnose diabetes mellitus, from the 778 people included in this study, 167 (21.5%) had disturbances of carbohydrate metabolism, being classified as patoglycemic and 611 persons (78.5%) had normal values of fasting glucose and 2 hours glucose during OGTT, being considered normoglycemic. From the 611 people who were classified as normal glucose tolerance, based on the currently used criteria for diagnosis of diabetes mellitus, a total of 44 persons (7.2%) had, however, the value of 1-hour glucose during OGTT ≥200mg%, which represents 5.6% of the entire group studied. Conclusions Patients with normal glucose tolerance and glucose ≥200mg% at 1 hour during OGTT represent a new subgroup of impaired glucose tolerance, which requires strict lifestyle advice and possibly pharmacological measures to prevent or delay progression to abnormal glucose tolerance.
42
Yoon, Jimin, Suk Gyu Ha, Youngwoo Suh, and Seung-Hyun Kim. "Efficacy of Low-dose Atropine Eyedrops in Myopic Progression in Elementary School Children." Journal of the Korean Ophthalmological Society 63, no. 5 (May 15, 2022): 455–60. http://dx.doi.org/10.3341/jkos.2022.63.5.455.
Full textAbstract:
Purpose: We analyzed the effects of low-dose atropine on myopic progression in elementary schoolchildren aged 6-11 years.Methods: Medical records were retrospectively reviewed before and after 6 months of low-dose atropine eyedrops. Myopia was defined as a spherical equivalent < -1 diopter. Low-dose atropine eyedrops (atropine sulfate 0.125% [w/v]) and artificial tear eyedrops (sodium hyaluronate 0.1% [w/v]) immediately afterwards were applied to both eyes daily, and all children regularly visited us for measurement of refractive power, axial length, pupil diameter, and near-point accommodation. symptoms (headache, light sensitivity, near-work disturbance, allergic reaction, dry eye, and poor night vision) were recorded.Results: A total of 116 patients were included. Atropine was prescribed for 65 patients, the remaining 51 patients constituted the control group. In the atropine group, the mean age was 10.2 ± 1.8 years and 23 patients (35.4%) were male. At the initial visit, the mean refractive power was -4.7 ± 2.1 diopters (D) (-1.0 to -10.5) and the mean axial length was 24.95 ± 1.02 mm (22.58-27.99). At the 6-month follow-up, the change of refractive power was -0.9 ± 1.1 D (-0.75 to -4.75) and the change of axial length was 0.47 ± 0.39 mm (0.01-1.6). However, 6 months after application of low-dose atropine eyedrops, the change of refractive power was -0.1 ± 0.2 D (0 to -0.25) and the change of mean axial length was 0.15 ± 0.23 mm (0-1.05). The mean pupil diameter was 6.7 ± 0.6 mm (5.3-9.3) and the near accommodation point was 6.1 ± 2.0 cm (3.1-11.0). Two patients (3.1%) complained of near-work disturbance but none stopped taking the eyedrops.Conclusions: Significant decreases in the changes of refractive power and axial length were evident in myopic elementary schoolchildren after low-dose atropine therapy. Low-dose atropine attenuates myopic progression without severe complications.
43
Tsuchiya, Kaoru, Masayuki Kurosaki, Shun Kaneko, Toru Kimura, Hiroyuki Marusawa, Hirotaka Arai, Takehiko Abe, et al. "A nationwide multicenter study in patients with unresectable hepatocellular carcinoma treated with lenvatinib in real world practice in Japan." Journal of Clinical Oncology 37, no. 4_suppl (February 1, 2019): 364. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.364.
Full textAbstract:
364 Background: Lenvatinib(LEN) has been approved as a single agent for patients with unresectable hepatocellular carcinoma (u-HCC) since Mar 2018 in Japan. A few results from a large sample size cohort of LEN therapy in real world practice has been reported. Therefore, we performed a retrospective nationwide multicenter study. Methods: A total of 116 u-HCC patients received LEN from March 2018 at 14 sites in Japan were registered. Tumour assessments in accordance with RECICT ver1.1 and modified RECIST were done using dynamic CT or MRI within 4-8 weeks and every 6-8 weeks thereafter. Adverse events (AEs) were graded according to the CTCAE ver4.0. Results: Median age was 72 (46-91)years, 88 (75.9%) patients were male, and median body weight was 60 (30-94) kg. The baseline liver function was Child-Pugh class A in 106 (91.4%) patients. Seventy-three (62.9%) patients were BCLC stage C. As the 2nd-line therapy (after sorafenib), 28 (24.1%) patients received LEN and 17 (14.7%) patients did as the 3rd-line (after regorafenib). Median observation time was 2.5 months and one patient died from HCC progression. The imaging findings of 49 (42.2%) patients were evaluated at 4-8weeks. Based on mRECIST, CR was shown in 3 (6.1%), PR in 14 (28.6%), SD in 23 (46.9%), and PD in 6 (12.2%). In the 3 patients, target lesions of liver showed PR, however bone metastases had progressed. [overall response rate (ORR) 34.7%, disease control rate (DCR) 81.6%]. ORR and DCR of tyrosine kinase inhibitor (TKI) naïve patients (n = 26) were 34.6% and 80.8%, while those of TKI experienced (n = 23) were 34.8% and 82.6%. The most common any-grade AEs were hypertension (52.0%), diarrhoea (32.1%), decreased appetite (63.5%) and fatigue (49.4%). Hand-food skin reaction (HFSR) was observed in 28% of patients. Conclusions: The efficacy of LEN therapy in real world practice in Japan was similar to the phase 3 clinical trial, even though elderly patients with lower body weight were included in this study. The incidence of HFSR during LEN in real world practice was lower than that of the sorafenib group in the phase 3 trial of LEN. Decrease appetite and fatigue must be carefully monitored and managed during LEN therapy.
44
Watts, Michael J., Stuart J. Ings, Carmen Balsa, Caroline Penn, David Leverett, and David C. Linch. "Successful Customization of Peripheral Blood Stem Cell Harvest Volume and Cell Concentration during Apheresis." Blood 104, no. 11 (November 16, 2004): 4992. http://dx.doi.org/10.1182/blood.v104.11.4992.4992.
Full textAbstract:
Abstract The high white cell counts associated with peripheral blood stem cell (PBSC) harvests make these products particularly prone to cellular damage during storage in the liquid phase. We recently described unexpectedly high thaw clonogenic losses of PBSC stored overnight at 4 deg C prior to cryopreservation. This was associated with high harvest white cell counts and delayed engraftment in a cohort of patients receiving autologous transplantation procedures (Watts et al 2003 Blood 102:113 abstract 127). We showed in this study that pre-diluting the cells in autologous plasma to a WBC of 100x10^9/L preserved clonogenic yields during liquid storage and post freeze-thaw and suggested an upper WBC threshold of 200x10^9/L for liquid storage. In many patients however, to achieve this count or below would require further dilution of the cells. Conversely, where cells are to be frozen immediately, it is advantageous to collect a low PBSC harvest volume to fully utilize cryostorage space and to achieve this without centrifugation. The present study demonstrates that the collection of either a low white count or low volume PBSC harvest can be controlled successfully using the GAMBRO BCT Spectra AutoPBSC apheresis machine (version 6.1) and avoids the need for any further laboratory manipulations. This machine allows the adjustment of the amount of autologous plasma used to rinse each cycle of PBSC cells into the collection bag and is referred to as the “plasma chase volume”. The plasma chase volume was set to maximum (20ml/cycle) for healthy donor harvests for shipping, and to minimum (4ml/cycle) where the cells were for immediate cryopreservation. A total of 114 harvests from 99 mobilised healthy donors were collected using the maximum plasma chase volume whereas 527 autograft harvests from 365 mobilised patients were collected using the lowest plasma chase setting. The median (range) WBC and volume of the 114 healthy donor harvests was 100 (28–174)x10^9/L and 473 (54–871) ml respectively. The median (range) WBC and volume of the 527 “small volume” harvests for cryopreservation was 254 (51–495)x10^9/L and 66 (20–180) ml respectively. To determine whether the maximal plasma chase setting affected the progenitor dose collected, we compared the first day harvest of the 99 mobilised healthy donors obtained with the Spectra autoPBSC with that from 114 healthy donors collected on the standard manual Spectra (n=63) and CS3000 (n=51) apheresis machines. The median (range) CD34+ cell yield was 361 (34–1,380), 291 (21–1,356) and 259 (37–738)x10^6 respectively. The first day median (range) CD34+ cell yield x10^6 of the 365 mobilised patients where small volume autograft harvests were collected on the Spectra AutoPBSC was 202 (0–7,569) compared to 195 (0–5,054) using the manual Spectra (n=142) and 152 (0–4,830) x10^6 using the CS3000 machine (n=813). Our policy is to dilute any harvest for storage/shipping with a nucleated cell count greater than 200x10^9/L with autologous plasma, but none of the donor harvests exceeded this threshold and no laboratory manipulation was required. In the case of the autograft harvests for immediate cryopreservation, 502/527(95%) of the collections were 100ml or less. In conclusion, this study demonstrates for the first time that the cell count and volume of the PBSC harvest required can be customized at apheresis, that this is not detrimental to progenitor yields and results in a product that is optimal for storage/shipping without laboratory intervention.
45
Erina, A. M., O. P. Rotar, V. N. Solntsev, S. A. Shalnova, A. D. Deev, E. I. Baranova, O. A. Konradi, S. A. Boytsov, and E. V. Shlyakhto. "Epidemiology of Arterial Hypertension in Russian Federation – Importance of Choice of Criteria of Diagnosis." Kardiologiia 59, no. 6 (June 27, 2019): 5–11. http://dx.doi.org/10.18087/cardio.2019.6.2595.
Full textAbstract:
Purpose. Assessment of prevalence of arterial hypertension (AH), need for prescription of antihypertensive therapy (AHT), and efficacy of AHT in Russian population in accordance with novel guideline of the American College of Cardiology/American Heart Association (“American recommendations”) on diagnosis and treatment of AH (2017).Materials and methods. Epidemiological study ESSE-RF (ЭССЕ-РФ) was carried out in 12 regions of Russian Federation (RF) with different climatic-geographic characteristics. Number of examined residents of RF aged 25–65 years was 20 652. The sample was stratified by gender and age. Examination included anthropometry, laboratory tests, blood pressure (BP) measurement with the OMRON tonometer. The SCORE scale was used for evaluation of risk of development of cardiovascular diseases (CVD). In American recommendations AH was defined as follows: 1-st degree – systolic BP (SBP) 130–139 and/or diastolic BP (DBP) 80–89 mm Hg, 2-nd degree – BP ≥140/90 mm Hg and/or presence of AHT. In recommendations of the European Society of Cardiology (2013, 2018) (“European recommendations”) AH was defined as BP ≥140/90 mm Hg and/or presence of AHT.Results. We analyzed data of examination of 20 607 participants – 7806 men (37.9%) and 12 801 women (62.1%). According to European recommendations AH was diagnosed in 10 347 persons (50.2%) – 3987 men (51.1%) men and 6 360 women (49.7%). According to American recommendations AH was registered in 14 853 persons (72.1%) – 6 059 men (77.6%) and 8 794 women (68.7%). AHT received 6324 persons (61.1% of those with AH); according to American recommendations, the onset of AHT was indicated to additional 620 persons with 1-st degree AH because of high CVD risk. Among all participants with AH (on and without AHT) strengthening of AHT for achievement of target BP level was required in 77.8 and 92.6% of patients according to European and American recommendations, respectively.Conclusion. Application of novel criteria of AH diagnosis from 2017 ACC/AHA guideline to Russian population would increase prevalence of AH up to 72.1%. Onset of AHT would be indicated in 13.8% of patients with 1-st degree AH, while in 93% of patients receiving AHT its strengthening would be required.
46
Demetrio, D., A. Magalhaes, M. Oliveira, R. Santos, and R. Chebel. "11 Invivo-derived embryo pregnancy rates at Maddox Dairy from 2008 to 2018." Reproduction, Fertility and Development 32, no. 2 (2020): 130. http://dx.doi.org/10.1071/rdv32n2ab11.
Full textAbstract:
Maddox Dairy, located in Riverdale, CA, USA, is a Holstein herd that milks 3500 cows with a 305-day mature-equivalent milk production of 12 800 kg, and they have been producing high genetic animals by embryo transfer (ET) since the early 1980s. Invivo-derived embryos from Holstein donors were transferred fresh (grade 1 or 2) or frozen (grade 1), at morula (4), early blastocyst (5), or blastocyst (6) stage, to virgin heifers (VH, natural oestrus, 13-15 months old) or lactating cows (LC, Presynch-Ovsynch, 86 days in milk, first or second lactation) 6 to 9 days after oestrus. Pregnancy diagnosis was done by transrectal ultrasonography at 32-46 days in VH and by the IDEXX PAG test at 30 days in LC. June, July, August, September, and October were called critical months (first service AI conception rate drops below 44%) and compared with the other months. The data from 32 503 ETs between January 2008 and December 2018 are summarised on Table 1. Pregnancy rates (PR) are lower for LC recipients than for VH. Embryo transfers performed 7 or 8 days after oestrus had higher PR in both types of recipients and embryos, but Day 6 and 9 oestrus are also used with fair results. The season does not seem to affect PR. There is not enough difference in the combination of stage and days from oestrus for invivo-derived embryos. These numbers do not belong to a planned experiment. Several management changes during the years were made, which make it very difficult to apply statistical methods to analyse the data correctly. They are used as a tool to make decisions in an attempt to improve future results. Table 1.Pregnancy rate (PR) of virgin heifers (top) and lactating cows (bottom)-fresh (SH) and frozen (OZ) invivo-derived embryo transfer1 Heat-months SH-ST4 SH-ST5 SH-ST6 SH-All OZ-ST4 OZ-ST5 OZ-ST6 OZ-All PR% n PR% n PR% n PR% n PR% n PR% n PR% n PR% n Heifers 6 d-CM 62 934 66 243 68 69 63 1246 56 473 58 219 62 42 57 734 6 d-OM 62 1623 67 489 69 211 64 2323 56 600 55 296 48 137 55 1033 6 d-T 62 2557 67 732 69 280 63 3569 56 1073 57 515 51 179 56 1767 7 d-CM 64 1506 68 495 67 221 65 2222 60 822 62 340 63 156 61 1318 7 d-OM 66 2723 68 1021 69 510 67 4254 57 1120 59 581 57 231 58 1932 7 d-T 66 4229 68 1516 69 731 67 6476 58 1942 60 921 60 387 59 3250 8 d-CM 65 1348 64 518 67 322 65 2188 59 595 64 258 63 108 61 961 8 d-OM 66 2166 68 886 70 510 67 3562 61 770 60 364 51 130 60 1264 8 d-T 66 3514 67 1404 69 832 66 5750 60 1365 62 622 56 238 60 2225 9 d-CM 60 109 56 43 70 20 60 172 60 5 33 6 50 4 47 15 9 d-OM 58 129 63 57 60 40 60 226 63 16 50 18 75 4 58 38 9 d-T 59 238 60 100 63 60 60 398 62 21 46 24 63 8 55 53 All-CM 64 3897 66 1299 67 632 65 5828 58 1895 61 823 63 310 60 3028 All-OM 65 6641 67 2453 69 1271 66 10 365 58 2506 58 1259 53 502 58 4267 All-T 65 10 538 67 3752 69 1903 66 16 193 58 4401 60 2082 57 812 59 7295 Lactating cows 6 d-CM 54 265 48 86 50 12 53 363 38 141 31 77 50 10 36 228 6 d-OM 49 463 52 203 45 56 50 723 46 101 48 54 59 27 48 182 6 d-T 51 728 51 289 46 68 51 1086 41 242 38 131 57 37 42 410 7 d-CM 54 755 59 274 56 103 55 1137 43 928 48 450 43 192 45 1570 7 d-OM 55 914 66 367 54 109 58 1393 46 1052 45 564 47 353 46 1969 7 d-T 55 1669 63 641 55 212 57 2530 45 1980 46 1014 46 545 45 3539 8 d-CM 63 252 68 82 76 33 65 368 48 219 56 80 42 33 50 332 8 d-OM 61 257 64 161 53 47 61 466 50 191 53 77 56 16 51 284 8 d-T 62 509 65 243 63 80 63 834 49 410 55 157 47 49 50 616 All-CM 56 1272 58 442 60 148 57 1868 44 1288 47 607 43 235 45 2130 All-OM 55 1634 62 731 51 212 56 2582 47 1344 46 695 48 396 47 2435 All-T 55 2906 60 1173 55 360 57 4450 45 2632 47 1302 46 631 46 4565 1ST=stage; CM=critical months (June, July, August, September, and October); OM=other months.
47
Obarevich, Ekaterina, Natalia Besova, Tatiana Titova, Elena Trusilova, Mikhail Davydov, Sergey Nered, Ivan Stilidi, and Elena Artamonova. "The real-world practiсe of surgery in patients with metastatic gastric cancer (mGC)." Journal of Clinical Oncology 38, no. 4_suppl (February 1, 2020): 363. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.363.
Full textAbstract:
363 Background: According to recent studies the results of treatment patients with initially mGC are still not sufficient: median overall survival varies between 6.1 and 12.4 months. The triplet-chemotherapy regimens demonstrate high efficacy and allow to downstage the disease and perform surgical treatment. Conversion treatment in stage IV GC is a modern trend and still an area of ongoing research. Methods: We analyzed the efficacy of first line chemotherapy (6-9 courses) for patients with mGC (n = 55) including the following regimens: 1) mFOLFIRINOX; 2) douplet: oxaliplatin/irinotecan + fluoropyrimidine; 3) triplet variations: docetaxel, platinum and fluoropyrimidine. 27/55 patients had > 2 metastatic sites, 2/55 patient - 5 metastatic sites. The most common localizations of metastases were peritoneum (n = 34) and retroperitoneal lymph nodes (n = 11). Unlike in REGATTA trial all patients underwent surgical treatment with curative intent followed by complete response of distant metastases after chemotherapy. For patients with ovarian metastases ovariectomy was also perfomed. Results: Median progression-free survival and median overall survival were 18.5 and 33.27 months, respectively and the 3-year survival rate was 43.5%. Multivariate analysis showed that clinically determined ascites (p = 0.023), linitis plastica (p = 0.022), tumor grade 3 (p = 0.014), present of lymphovascular invasion (p = 0.037), absence of grade III-IV pathomorphosis (p = 0.037) and treatment free interval before surgery < 3.4 month (p = 0.046) were poor independent prognostic factors. Conclusions: Surgery after effective combination chemotherapy may have significant clinical efficacy for selected patients with initially unresectable gastric cancer. According to our data the optimal time for surgery is a 3.4 and more months treatment-free interval in the absence of disease progression.
48
Aadland, Eivind, and Sigmund Alfred Anderssen. "Treadmill Calibration of the Actigraph GT1M in Young-to-Middle-Aged Obese-to-Severely Obese Subjects." Journal of Obesity 2012 (2012): 1–8. http://dx.doi.org/10.1155/2012/318176.
Full textAbstract:
To understand the impact of physical activity (PA) on health, valid accelerometer count cut points must be applied to measure PA. Because cut points may be population specific, we aimed to establish accelerometer cut points for moderate PA (MPA) and vigorous PA (VPA) (defined as ≥3 and ≥6 metabolic equivalents, resp.) in young-to-middle-aged obese-to-severely obese subjects. Data from 42 subjects (11 men; body mass index39.8±5.7; age43.2±9.2years) who performed a treadmill calibration using the Actigraph GT1M, were analyzed using ordinary linear regression (OLR), linear mixed model regression (MIX), and receiver operating characteristics curves (ROC 1; ROC 2). Cut points obtained from the models were quite different (612 to 1646 counts/min for MPA; 3061 to 7220 counts/min for VPA). We argue that the MIX approach, which resulted in cut points of 612 and 4980 counts/min for MPA and VPA, respectively, is the most appropriate method to establish accelerometer cut points in this setting. We conclude that accelerometer cut points are lower in young-to-middle-aged obese-to-severely obese subjects compared to young normal-weight subjects and that care should be taken when analyzing PA level in groups that vary in age and degree of obesity.
49
Andria, Andria, Catur Herison, Sigit Sudjatmiko, and Nurwita Dewi. "Pertumbuhan dan Hasil Dua Belas Genotipe Kacang Hijau pada Beberapa Dosis Pupuk Kandang Sapi di Lahan Ultisol." Akta Agrosia 19, no. 1 (June 30, 2016): 11–19. http://dx.doi.org/10.31186/aa.19.1.11-19.
Full textAbstract:
One major problem of low mungbean production in Indonesia is the lack of high yielding varieties for marginal land. A study was done with an objective to compare growth and yield of twelve mung bean genotypes on ultisol fertilized with several doses of cow manure. Twelve mung bean genotypes were grown in a field under a randomized complete block design arranged in a Split Plot Design with 3 replications. The Main Plots were four doses of cow manure, i.e. 0, 3, 6 or 9 ton.ha-1 and the Sub-Plots were twelve mungbean genotypes, i.e. VR 3, VR 61, VR 88, VR 200, VR 204 K, VR 213 K, VR 266 ct, VR 341, VR 368, VR 601 m, VR 222 Walet and VR 1074 Vinna-1. The result showed that the interaction between cow manure doses and mungbean genotypes was only occured on number of leaf. Genotype VR 61 demonstrated the highest plant stature, the greatest pod number, the heafiest pod and seeds per plant. Increasing dose of cow manure until 9 tons.ha-1did not reach the optimum level for the growth and yield of mungbean genotypes yet, except on the number of leaf variable on genotype VR 3, VR 88, VR 200, VR 266 ct and VR 601.
50
Xu, Binghe, Qingyuan Zhang, Pin Zhang, Xichun Hu, Wei Li, Zhongsheng Tong, Tao Sun, et al. "Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 1002. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1002.
Full textAbstract:
1002 Background: Dalpiciclib (SHR6390), a novel CDK4/6 inhibitor, as monotherapy has demonstrated tolerability and preliminary antitumor activity in pretreated HR+/HER2− advanced breast cancer (ABC). Here we evaluated dalpiciclib with fulvestrant in ABC. Methods: In this randomized, double-blind, phase 3 trial, patients (pts) with HR+/HER2− locally advanced or metastatic breast cancer who had relapsed or progressed on previous endocrine therapy were enrolled. Eligible pts were randomized 2:1 to receive dalpiciclib (dalp; 150 mg po qd, d1-21, q4w) or placebo (PBO) with fulvestrant (fulv; 500 mg im, cycle 1 d1, d15, then d1 q4w). The primary endpoint was investigator (INV)-assessed PFS. As of Nov. 15, 2020, 162 (71.4% of total projected) events of disease progression or death had occurred and a preplanned interim analysis was done. The corresponding superiority boundary was 1-sided P = 0.0080 (Lan-DeMets [O’Brien-Fleming] boundary). Results: Overall, 361 pts were randomized to receive dalp-fulv (n = 241) or PBO-fulv (n = 120). With a median follow-up of 10.5 mo, dalp-fulv significantly improved INV-assessed PFS versus PBO-fulv (median, 15.7 [95% CI 11.1-NR] vs 7.2 [95% CI 5.6-9.2] mo; HR, 0.42 [95% CI 0.31-0.58]; P < 0.0001). PFS per IRC were consistent with INV assessment (Table). The benefit of dalpiciclib extended beyond initial study treatment based on time to first subsequent chemotherapy (TFSCT; HR, 0.47 [95% CI 0.32-0.69]; P < 0.0001). OS data were not mature with a total of 25 deaths documented. Median duration of exposure was 9.4 (IQR, 4.3-11.4) mo with dalpiciclib and 9.9 (4.7-11.9) mo with fulvestrant in the dalp-fulv group and was 6.1 (3.7-11.0) mo with fulvestrant in the PBO-fulv group. The most common (incidence ≥3%) grade 3 or 4 AEs with dalp-fulv were neutropenia (84.2%; vs 0% with PBO-fulv) and leukopenia (62.1%; vs 0%). Treatment discontinuation due to AE was reported for 2.5% of pts with dalp-fulv vs 3.3% with PBO-fulv. The incidence of SAE was 5.8% with dalp-fulv vs 6.7% with PBO-fulv. Conclusions: The study met its primary endpoint, demonstrating that dalpiciclib plus fulvestrant significantly improved PFS versus placebo plus fulvestrant, with a manageable safety profile. Our findings support dalpiciclib plus fulvestrant as a new treatment option in pts with HR+/HER2- ABC who relapsed or progressed on endocrine therapy. Clinical trial information: NCT03927456 .[Table: see text]